TWI710560B - 用於治療呼吸疾病之jak激酶抑制劑化合物 - Google Patents

用於治療呼吸疾病之jak激酶抑制劑化合物 Download PDF

Info

Publication number
TWI710560B
TWI710560B TW105135436A TW105135436A TWI710560B TW I710560 B TWI710560 B TW I710560B TW 105135436 A TW105135436 A TW 105135436A TW 105135436 A TW105135436 A TW 105135436A TW I710560 B TWI710560 B TW I710560B
Authority
TW
Taiwan
Prior art keywords
alkyl
compound
ethyl
hydrogen
imidazo
Prior art date
Application number
TW105135436A
Other languages
English (en)
Chinese (zh)
Other versions
TW201726673A (zh
Inventor
保羅 R 費瑟里
約翰 R 傑柯森
安－瑪莉 柏索里爾
蓋瑞 E L 布蘭德
梅莉沙 佛羅瑞
姜嵐
卡梅朗 史密斯
史蒂芬 D E 蘇利文
羅利 珍 凡歐丹
彼瑞 珍 寇森
吉尼 提摩西 法斯
麥洛史夫 瑞帕達
諾瓦 班傑明
瑪塔 代布洛斯
凡凱特 R 泰拉狄
Original Assignee
美商施萬生物製藥研發Ｉｐ有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商施萬生物製藥研發Ｉｐ有限責任公司 filed Critical 美商施萬生物製藥研發Ｉｐ有限責任公司
Publication of TW201726673A publication Critical patent/TW201726673A/zh
Application granted granted Critical
Publication of TWI710560B publication Critical patent/TWI710560B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW105135436A 2015-11-03 2016-11-02 用於治療呼吸疾病之jak激酶抑制劑化合物 TWI710560B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562250113P 2015-11-03 2015-11-03
US62/250,113 2015-11-03

Publications (2)

Publication Number Publication Date
TW201726673A TW201726673A (zh) 2017-08-01
TWI710560B true TWI710560B (zh) 2020-11-21

Family

ID=57442794

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105135436A TWI710560B (zh) 2015-11-03 2016-11-02 用於治療呼吸疾病之jak激酶抑制劑化合物

Country Status (22)

Country Link
US (6) US10100049B2 (enExample)
EP (1) EP3371186A1 (enExample)
JP (1) JP6800969B2 (enExample)
KR (1) KR20180073687A (enExample)
CN (1) CN108349972B (enExample)
AU (1) AU2016350816B2 (enExample)
BR (1) BR112018008966B1 (enExample)
CA (1) CA3001542C (enExample)
CL (1) CL2018001145A1 (enExample)
CO (1) CO2018005640A2 (enExample)
EA (1) EA034914B1 (enExample)
HK (1) HK1252685A1 (enExample)
IL (1) IL258772B (enExample)
MX (1) MX374605B (enExample)
MY (1) MY195427A (enExample)
NZ (1) NZ741737A (enExample)
PH (1) PH12018500828B1 (enExample)
SA (1) SA518391470B1 (enExample)
TW (1) TWI710560B (enExample)
UA (1) UA123633C2 (enExample)
WO (1) WO2017079205A1 (enExample)
ZA (1) ZA201802496B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY195427A (en) 2015-11-03 2023-01-20 Theravance Biopharma R&D Ip Llc Jak Kinase Inhibitor Compounds for Treatment of Respiratory Disease
ES2864035T3 (es) 2015-11-03 2021-10-13 Topivert Pharma Ltd Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina y 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inhibidores de la quinasa janus
US10556901B2 (en) 2015-11-03 2020-02-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as Janus kinase inhibitors
AU2018231032B2 (en) 2017-03-09 2021-08-19 Theravance Biopharma R&D Ip, Llc JAK inhibitors containing a 4-membered heterocyclic amide
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
RU2764979C2 (ru) 2017-05-01 2022-01-24 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи Способы лечения с использованием соединения-ингибитора jak
WO2018204236A1 (en) * 2017-05-01 2018-11-08 Theravance Biopharma R&D Ip, Llc Crystalline forms of a jak inhibitor compound
US20200281857A1 (en) 2017-11-22 2020-09-10 Dauntless 1, Inc. Therapeutic compound formulations
WO2019246273A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
WO2020051135A1 (en) * 2018-09-04 2020-03-12 Theravance Biopharma R&D Ip, Llc Process for preparing jak inhibitors and intermediates thereof
DK3837258T3 (da) 2018-09-04 2024-07-22 Theravance Biopharma R&D Ip Llc Dimethyl amino azetidine amides as jak inhibitors
ES2955717T3 (es) 2018-09-04 2023-12-05 Theravance Biopharma R&D Ip Llc Amidas heterocíclicas de 5 a 7 elementos como inhibidores de JAK
JP2022506111A (ja) * 2018-10-29 2022-01-17 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ｊａｋ阻害剤としての２－アザビシクロヘキサン化合物
AU2019384733A1 (en) 2018-11-19 2021-06-24 New York University Inhibitors of gli1 as therapeutic agents
AU2020228799B2 (en) 2019-02-25 2024-12-05 Henan Medinno Pharmaceutical Technology Co., Ltd. JAK inhibitor compound and use thereof
CN114075200A (zh) * 2020-08-14 2022-02-22 河南迈英诺医药科技有限公司 用于治疗重症肺炎的jak抑制剂化合物
MA55201A (fr) 2019-03-05 2022-01-12 Incyte Corp Inhibiteurs de la voie jak1 pour le traitement d'un dysfonctionnement chronique de l'allogreffe pulmonaire
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021136345A1 (zh) * 2019-12-30 2021-07-08 路良 Jak抑制剂化合物及其用途
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TW202144343A (zh) 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
WO2022178215A1 (en) 2021-02-19 2022-08-25 Theravance Biopharma R&D Ip, Llc Amino amide tetrahydro imidazo pyridines as jak inhibitors
CN117083273A (zh) 2021-03-26 2023-11-17 施万生物制药研发Ip有限责任公司 Jak抑制剂化合物的二盐酸盐的晶型
TW202317550A (zh) * 2021-06-25 2023-05-01 美商施萬生物製藥研發 Ip有限責任公司 作為jak抑制劑之咪唑吲唑化合物
CN114181055A (zh) * 2021-12-21 2022-03-15 苏州楚凯药业有限公司 1-苄氧基-4-溴-5-乙基-2-氟苯的制备方法
JP2025515078A (ja) 2022-05-05 2025-05-13 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー 噴霧経口吸入による送達のためのネズルシチニブ

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013014567A1 (en) * 2011-07-27 2013-01-31 Pfizer Limited Indazoles

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
WO2005009389A2 (en) 2003-07-23 2005-02-03 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
CA2673125C (en) 2006-10-19 2015-04-21 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
CA2727036C (en) 2008-06-20 2017-03-21 Genentech, Inc. Triazolopyridine jak inhibitor compounds and methods
WO2010039825A2 (en) 2008-10-01 2010-04-08 Array Biopharma Inc. IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ｔｔｋ阻害作用を有するインダゾール誘導体
CA2756989A1 (en) 2009-04-03 2010-10-07 Douglas Burdi Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
CN106420756A (zh) 2009-07-28 2017-02-22 里格尔药品股份有限公司 抑制jak途径的组合物和方法
NO3001903T3 (enExample) 2009-12-21 2018-03-24
EP2338888A1 (en) 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
EA024026B1 (ru) 2010-11-25 2016-08-31 Рациофарм Гмбх Новые соли и полиморфные формы афатиниба
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
TW201513861A (zh) * 2013-01-17 2015-04-16 Galapagos Nv 用於治療退化性及發炎疾病之新穎化合物
BR112016012262B1 (pt) 2013-12-05 2021-04-13 Pfizer Inc Acrilamidas heterocíclicas farmaceuticamente ativas e composições para tratar e prevenir condições mediadas por jac
MD20160121A2 (ro) 2014-05-14 2017-05-31 Pfizer Inc. Pirazolopiridine şi pirazolopirimidine
WO2016026078A1 (en) 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
MY195427A (en) 2015-11-03 2023-01-20 Theravance Biopharma R&D Ip Llc Jak Kinase Inhibitor Compounds for Treatment of Respiratory Disease
US10556901B2 (en) 2015-11-03 2020-02-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as Janus kinase inhibitors
ES2864035T3 (es) 2015-11-03 2021-10-13 Topivert Pharma Ltd Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina y 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inhibidores de la quinasa janus
AU2018231032B2 (en) 2017-03-09 2021-08-19 Theravance Biopharma R&D Ip, Llc JAK inhibitors containing a 4-membered heterocyclic amide
RU2764979C2 (ru) 2017-05-01 2022-01-24 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи Способы лечения с использованием соединения-ингибитора jak
WO2018204236A1 (en) 2017-05-01 2018-11-08 Theravance Biopharma R&D Ip, Llc Crystalline forms of a jak inhibitor compound
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
WO2020051135A1 (en) 2018-09-04 2020-03-12 Theravance Biopharma R&D Ip, Llc Process for preparing jak inhibitors and intermediates thereof
ES2955717T3 (es) 2018-09-04 2023-12-05 Theravance Biopharma R&D Ip Llc Amidas heterocíclicas de 5 a 7 elementos como inhibidores de JAK
DK3837258T3 (da) 2018-09-04 2024-07-22 Theravance Biopharma R&D Ip Llc Dimethyl amino azetidine amides as jak inhibitors
JP2022506111A (ja) 2018-10-29 2022-01-17 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ｊａｋ阻害剤としての２－アザビシクロヘキサン化合物
CN117083273A (zh) 2021-03-26 2023-11-17 施万生物制药研发Ip有限责任公司 Jak抑制剂化合物的二盐酸盐的晶型

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013014567A1 (en) * 2011-07-27 2013-01-31 Pfizer Limited Indazoles

Also Published As

Publication number Publication date
NZ741737A (en) 2023-11-24
US20170121327A1 (en) 2017-05-04
US20200087303A1 (en) 2020-03-19
HK1252685A1 (zh) 2019-05-31
UA123633C2 (uk) 2021-05-05
AU2016350816B2 (en) 2020-06-25
JP6800969B2 (ja) 2020-12-16
MX374605B (es) 2025-03-06
CA3001542C (en) 2021-02-16
TW201726673A (zh) 2017-08-01
BR112018008966A2 (pt) 2018-11-27
KR20180073687A (ko) 2018-07-02
AU2016350816A1 (en) 2018-05-17
US10100049B2 (en) 2018-10-16
EA034914B1 (ru) 2020-04-06
BR112018008966B1 (pt) 2023-05-02
US20220306624A1 (en) 2022-09-29
US20210130351A1 (en) 2021-05-06
SA518391470B1 (ar) 2021-03-31
JP2018531982A (ja) 2018-11-01
US11718616B2 (en) 2023-08-08
US10526330B2 (en) 2020-01-07
US20190106420A1 (en) 2019-04-11
MX2018005446A (es) 2018-08-01
IL258772A (en) 2018-06-28
CN108349972A (zh) 2018-07-31
US11299492B2 (en) 2022-04-12
CL2018001145A1 (es) 2018-07-06
CN108349972B (zh) 2021-06-08
PH12018500828A1 (en) 2018-10-29
EA201891091A1 (ru) 2018-12-28
PH12018500828B1 (en) 2023-06-30
ZA201802496B (en) 2025-01-29
EP3371186A1 (en) 2018-09-12
US20180319796A1 (en) 2018-11-08
US10183942B2 (en) 2019-01-22
CO2018005640A2 (es) 2018-05-31
IL258772B (en) 2021-01-31
WO2017079205A1 (en) 2017-05-11
CA3001542A1 (en) 2017-05-11
US10913740B2 (en) 2021-02-09
MY195427A (en) 2023-01-20

Similar Documents

Publication Publication Date Title
TWI710560B (zh) 用於治療呼吸疾病之jak激酶抑制劑化合物
US10370338B2 (en) Benzazepine dicarboxamide compounds with tertiary amide function
AU2019204244B2 (en) Cyclopropylamines as lsd1 inhibitors
US10323037B2 (en) Aminopyridazinone compounds as protein kinase inhibitors
TWI746178B (zh) 製備作為jak激酶抑制劑之萘啶化合物之方法
US10562891B2 (en) Quinazolinones as PARP14 inhibitors
EP3768272B1 (en) Jak inhibitors
US8623877B2 (en) Substituted N-heteroaryl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof
CN117098765A (zh) 作为詹纳斯激酶抑制剂的杂环衍生物
HK40096740A (zh) 杂芳基甲酰胺化合物
HK40002463A (en) Benzazepine dicarboxamide compounds with tertiary amide function
HK40002463B (en) Benzazepine dicarboxamide compounds with tertiary amide function

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees